atorvastatin / Generic mfg. - LARVOL DELTA

Real-world impact of lipophilic statins on survival outcomes in polycythemia vera and essential thrombocythemia (ASH 2025) - "Preclinical studies have suggested that lipophilic statins—such as simvastatin, lovastatin, and atorvastatin—may disrupt membrane lipid rafts, thereby interfering with JAK2-V617F–mediated signaling... In this large, real-world cohort study, lipophilic statin use was associated with a significant reduction in all-cause mortality among patients with polycythemia vera or essential thrombocythemia. These findings highlight the potential role of statins as adjunctive therapy in myeloproliferative neoplasms and warrant further prospective evaluation."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Chronic Eosinophilic Leukemia • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis

Rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for R/R Acute Myeloid Leukemia (ASH 2025) - "She was started on treatment with azacitidine, venetoclax, and magrolimab and achieved MRD-negative CR after cycle 1, then went on to complete 6 cycles of therapy, followed by 4 cycles of maintenance therapy with combination decitabine/cedazuridine and venetoclax prior to relapse. She was then treated with combination decitabine/cedazuridine, venetoclax, and ivosidenib...Azacitidine was discontinued after C33, at which time she continued on enasidenib monotherapy...She was on a stable dose of atorvastatin at the time of this event and had recently started azithromycin for symptoms of upper respiratory tract infection...al 2015). We hypothesize that rhabdomyolysis observed with IDH inhibitors may reflect a convergence of metabolic stressors, particularly in susceptible populations such as elderly patients with low muscle mass, and those on concomitant statins."

Clinical • Acute Myelogenous Leukemia • Brain Cancer • Constipation • Gastroenterology • Gastrointestinal Disorder • Glioma • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Musculoskeletal Pain • Myelodysplastic Syndrome • Respiratory Diseases • Solid Tumor • Thrombocytopenia • IDH1 • IDH2

Warm autoimmune hemolytic anemia following epstein-barr virus reactivation: An uncommon clinical association (ASH 2025) - "His only medications were atenolol and atorvastatin, and he denied use of herbal supplements or over-the-counter drugs... Warm AIHA is most commonly idiopathic but can also occur secondary to various conditions, including rheumatologic diseases (e.g., systemic lupus erythematosus), chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, certain medications (e.g., cephalosporins, piperacillin), and infections...Initial corticosteroid therapy varies widely during the first 72 hours, ranging from 1–2 mg/kg of prednisone every 8–12 hours to high-dose intravenous methylprednisolone (250–1000 mg/day)...In cases refractory to steroids, additional therapies such as mycophenolate mofetil or sirolimus may be considered. This case highlights a rare presentation of warm AIHA likely triggered by EBV reactivation, an association that is infrequently reported in the literature."

Clinical • Anemia • Autoimmune Hemolytic Anemia • Chronic Lymphocytic Leukemia • Cytomegalovirus Infection • Dyslipidemia • Epstein-Barr Virus Infections • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Leukemia • Lupus • Lymphoma • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Rheumatology • Systemic Lupus Erythematosus • HP

Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms (ASH 2025) - "Among patients on statins, a subgroup analysis wasperformed to assess the effect of high-intensity statin use (rosuvastatin ≥ 20 mg or atorvastatin ≥ 40 mg)compared with low or medium intensity statins... In patients with MPNs, statin use was associated with a reduced risk of arterial thrombosisand heart failure hospitalization, but not with hematologic progression or all-cause mortality. Notably, theintensity of statin therapy did not correlate with clinical outcomes among statin-treated patients. Thesefindings suggest that statins may provide meaningful cardiovascular protection in individuals with MPN,yet appear to be underutilized even among those with established clinical indications."

Clinical • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Essential Thrombocythemia • Heart Failure • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Polycythemia Vera • Thrombocytosis • Thrombosis • CALR • JAK2

Lysophosphatidylcholine-induced macrophage polarization imbalance and functional dysregulation in immune thrombocytopenia (ASH 2025) - "In this study, we investigated whether LPCmodulates macrophage polarization and function in ITP patients via metabolic reprogramming.Furthermore, we evaluated the therapeutic efficacy of combined dexamethasone (DXM) and atorvastatin(AT) treatment, both in vitro and in an active ITP murine model.Methods Bone marrow (BM) samples were collected from 61 ITP patients and 46 healthy controls (HCs) at theDepartment of Hematology, Qilu Hospital of Shandong University, China. Additionally, LPC (16:0/0:0) induced the polarization of BMmacrophages toward M1 phenotype, while DXM reversed this shift, promoting M2 polarization.Conclusions Our study identifies LPC (16:0/0:0)-mediated metabolism-immunity crosstalk of macrophages as acentral pathogenic mechanism in ITP. We propose that the DXM–AT combination strategy may restoreimmune homeostasis by concurrently regulating metabolic and immune pathways."

Hematological Disorders • Immune Thrombocytopenic Purpura • Inflammation • Metabolic Disorders • Thrombocytopenia • Thrombocytopenic Purpura • CCR2 • CD68 • IL10

Injectable pentosan polysulfate: A novel cause of heparin-induced thrombocytopenia and stroke (ASH 2025) - "Aspirin and Atorvastatin were initiated, and Clopidogrel was deferred due to continuedthrombocytopenia.Due to the unusual presentation of ischemic stroke and isolated thrombocytopenia in a young femalewithout traditional risk factors, a comprehensive diagnostic evaluation was pursued. PPS was therefore identified as thelikely HIT trigger and the patient was treated with Argatroban and transitioned to Apixaban, with plateletcount recovery to 204x10³/μL.This case illustrates the importance of maintaining a broad differential when encountering unexplainedthrombocytopenia and thrombosis, as HIT may arise from unconventional exposures. Obtaining adetailed medication history, which includes unregulated and non-prescribed medications, is essential toidentifying a diagnosis."

Cardiovascular • Hematological Disorders • Immunology • Interstitial Cystitis • Ischemic stroke • Osteoarthritis • Rheumatology • Thrombocytopenia

Induced ubiquitination bypasses canonical ERAD to drive ER protein degradation. (PubMed, bioRxiv) - "Targeted protein degradation has transformed drug discovery. Nearly one-third of the proteome reside in or transit the endoplasmic reticulum (ER), a compartment rich in therapeutically relevant but structurally complex targets. Whether these ER proteins can be broadly degraded using PROTACs has remained unknown. Here, we define the minimal requirements for degrading ER membrane proteins by recruiting cytosolic E3 ligases. Using chemical-genetic tools, genetic screens, and a statin-based degrader, we show that ubiquitination engages the VCP extraction machinery, enabling degradation of diverse ER membrane proteins independent of canonical ER-associated degradation components. These findings reveal a ubiquitin-driven route for membrane protein turnover, expand the landscape of druggable ER proteins, and establish principles for designing degraders operating in the early secretory pathway."

Journal • Targeted Protein Degradation • CRBN

Highly Sensitive and Selective Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study. (PubMed, Biomed Chromatogr) - "The validated method was successfully applied to a pharmacokinetic study of a 10 mg oral formulation of upadacitinib and atorvastatin in rats. The pharmacokinetic results confirmed the applicability of the method for the reliable and simultaneous determination of both analytes in rat plasma."

Journal • PK/PD data • Preclinical

Break Away From the Hemodynamic "Gray Zone": Plaque Regression in a Non-Culprit Lesion of an NSTE-ACS. (PubMed, JACC Case Rep) - "A shared decision with the patient was made to defer intervention and instead commence intensive optimal medical therapy including dual antiplatelet therapy, a beta-blocker, and intensive lipid-lowering therapy with atorvastatin and evolocumab. At the 3-month follow-up, the patient reported complete relief of chest tightness, with a 73.6% reduction in his low-density lipoprotein cholesterol, accompanied by remarkable plaque regression, stabilization, and functional improvement."

Journal • Acute Coronary Syndrome • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders

Identifying metabolic vulnerabilities of recurrent IDH1-R132H mutant glioma by high throughput screening (SNO 2025) - "Notable target pathways include folate metabolism and de novo thymidylate synthesis (methotrexate, raltitrexed, 5-FU), p97 AAA ATPase/VCP chaperone (CB-5083, ML240, eeyarestatin I), mevalonate pathway (Ro 48-8071 fumarate, atorvastatin calcium), and the BCL-2 family (Navitoclax, ABT-737). We are validating these drugs across a panel of patient-derived IDH-mutant gliomasphere models, and examining the combinatorial effects of these agents with vorasidenib and CDK4/6 inhibitors. Our results provide insight into important metabolic pathway dependencies in recurrent IDH1-R132H mutant gliomas that have targeting potential."

IO biomarker • Brain Cancer • Glioma • Oligodendroglioma • Solid Tumor • BCL2 • IDH1 • NAMPT

Pharmacological prevention in cardio-oncology: from bench-to-bedside. (PubMed, Heart Fail Rev) - "Neurohormonal blockers, including ACE inhibitors, ARBs, and β-blockers, constitute the foundation of prevention, although their efficacy varies: combinations such as ACEi/ARB with βB yield mixed outcomes, whereas carvedilol offers antioxidant benefits beyond β-blockade. Sacubitril/valsartan (ARNI) has demonstrated improvements in global longitudinal strain and LVEF preservation in the SARAH trial, albeit with associated hypotension risks. Aldosterone antagonists show potential, with spironolactone preserving LVEF and diastolic function, though eplerenone has not shown significant effects. Statins present conflicting data; the STOP-CA trial supports atorvastatin for LVEF preservation, while the PREVENT and SPARE-HF trials found no benefit. Emerging evidence suggests sodium-glucose cotransporter-2 inhibitors (SGLT2i), such as dapagliflozin and empagliflozin, as promising agents, with preclinical and early clinical data indicating cardioprotection through metabolic..."

Journal • Review • Cardiovascular • Hypotension • Metabolic Disorders • Oncology • ICOS

Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial. (PubMed, Front Neurol) - P4 | "In this study, a total of 100 patients with AIS were included for the current analysis (n = 50 for combination therapy of evolocumab and atorvastatin, PI group, n = 50 for atorvastatin monotherapy, AT group). http://www.chictr.org.cn; Identifier: ChicTR2200059445. Date of registration: 29 April 2022."

Clinical • Journal • Cardiovascular • Ischemic stroke • Oncology • CXCL8 • IL6 • TNFA

Atorvastatin ameliorates chronic subdural hematomas by interrupting the 'chronic subdural hematoma cycle' via inhibition of the inflammatory response. (PubMed, Exp Ther Med) - "Collectively, these findings suggest that atorvastatin may disrupt the 'CSDH cycle' by modulating critical inflammatory, angiogenic and fibrinolytic mechanisms, providing a scientific rationale for its therapeutic application in CSDH management. Further in vivo studies are warranted to validate these preliminary observations and to explore clinical translation to the clinic."

Journal • CNS Disorders • Hematological Disorders • Inflammation • Oncology • CXCL8 • IL6 • MMP9 • SERPINE1 • TNFA

Effect of statin therapy on renal and lipid outcomes in CKM syndrome stage 2: a meta-analysis of randomized controlled trials. (PubMed, BMC Nephrol) - "Sensitivity analysis including a borderline CKM syndrome 2-3 trial characterized by higher renal risk, longer duration, and high-intensity atorvastatin rendered both renal and lipid outcomes statistically significant without altering effect direction. These findings suggest that statin therapy confers robust lipid-lowering efficacy and potential renoprotective effects in early CKM syndrome stages, particularly under conditions of greater baseline metabolic or renal burden. Statins may therefore serve as an early metabolic-renal intervention, warranting further validation in larger, stage-specific clinical trials."

Journal • Retrospective data • Cardiovascular • Metabolic Disorders

Engineered biodegradable polymeric nanoparticles injectable system of atorvastatin for improved therapeutic activity. (PubMed, Sci Rep) - "Characterization of selected formulation with analytical techniques like FT-IR, XRD, TG-DSC confirmed that the drug was functionally active in the polymeric systems without significant alterations. Therefore, the synthesized formulation was proven to be effective in improving in vitro dissolution without significant loss, which could improve the in vivo bioavailability of Atorvastatin by enhancing solubility, absorption, and permeation in the physiological system."

Journal • Cardiovascular • Dyslipidemia

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Central South University | N=200 ➔ 400

Enrollment change • CNS Disorders • Psychiatry • Schizophrenia

Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy (clinicaltrials.gov) - P1/2 | N=60 | Completed | Sponsor: Minia University | Recruiting ➔ Completed | Trial completion date: Jun 2026 ➔ Oct 2025 | Trial primary completion date: Mar 2026 ➔ Jul 2025

Adverse events • Trial completion • Trial completion date • Trial primary completion date • Solid Tumor

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Onconic Therapeutics Inc.

New P1 trial

EURO-CBI: A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (clinicaltrials.gov) - P3 | N=1652 | Recruiting | Sponsor: Aarhus University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease

Lysine p-nitroanilide impairs cellular energetics and potentiates statin-induced cytotoxicity in RD rhabdomyosarcoma cells. (PubMed, PLoS One) - "Leveraging the observed sensitivity of muscle cells to atorvastatin in clinical settings and utilizing untargeted metabolomic analysis of atorvastatin-treated RD rhabdomyosarcoma cells, we identified reduced levels of aminoadipic acid, an intermediate in lysine catabolism...However, we demonstrated that it is catabolically cleaved to p-nitroanilide, with this molecule driving the cytotoxic activity observed in our experiments. Although lysine metabolism was not fully suppressed by lysine-p-nitroanilide, these findings provide valuable insights for developing novel therapies for rhabdomyosarcoma."

Journal • Dyslipidemia • Metabolic Disorders • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor • AMPK

Cross-Sectional and Longitudinal Analyses of the Association Between Statin Use and Age-Related Hearing Loss. (PubMed, Drugs Aging) - "Overall, the findings suggest statin benefits for mid-to-high frequency hearing for middle-aged to older adults at early stages of ARHL. On the basis of evidence suggesting that some statins have beneficial effects on hearing, well-controlled clinical trials are needed to examine effects of statin use and statin types on ARHL in the general population."

Clinical • Journal • Otorhinolaryngology

Frontal Burr-Hole Compared with Parietal Burr-Hole in the Management of Chronic Subdural Hematoma: A Single-Center, Randomized Controlled, Noninferiority Trial. (PubMed, J Neurotrauma) - P=N/A | "All patients received postoperative atorvastatin combination therapy...These findings establish noninferiority of frontal burr-hole while demonstrating reduced postoperative pneumocephalus, supporting its clinical preference and warranting future superiority trials. (Trial registration: chictr.org.cn, ChiCTR2000033967)."

Head-to-Head • Journal • CNS Disorders • Infectious Disease • Pneumonia • Respiratory Diseases

In-Silico Screening of HMG-CoA Reductase Inhibition Potential from Anredera cordifolia (Ten.) Steenis and Elephantopus scaber Linn. (PubMed, Acta Med Philipp) - "The molecular docking results showed that three active compounds from Anredera cordifolia namely Ursolic acid, Calenduloside E, and Larreagenin A had a more negative binding energy compared to atorvastatin...Both Anredera cordifolia and Elephantopus scaber plants showed potential as antihypercholesterolemic drugs through inhibition of HMG-CoA reductase activity, showed drug-likeness, and were able to be absorbed well in the intestines and had no penetration into the blood-brain barrier. Further studies are needed both in vitro and in vivo to examine the therapeutic effects of these two plants."

Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Metabolic Disorders

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. (PubMed, BMJ Ment Health) - "There is currently not enough evidence to guide the prescription of statins for psychiatric symptom improvement in patients with SMI. If there is an effect of statins, it may be through specific statin-antipsychotic combinations."

Journal • PK/PD data • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Association Between Statin Use and Glaucoma Risk: A Population-Based Study. (PubMed, Invest Ophthalmol Vis Sci) - "Statin use, particularly atorvastatin and rosuvastatin, is associated with an increased risk of ocular hypertension and POAG among patients with hyperlipidemia. The risk appears to increase with longer durations of statin use."

Journal • Cardiovascular • Dyslipidemia • Glaucoma • Ophthalmology